Recent developments include ResMed's Q4 earnings call and financial results showing revenue growth and earnings increases, alongside portfolio optimization moves and market reactions.

• ResMed held its Q4 earnings call highlighting revenue growth and operational updates [N2].
• The company reported Q4 earnings and revenues that topped estimates, with year-over-year revenue increases [N5].
• Despite the Q4 earnings beat and revenue growth, ResMed's stock declined, reflecting market dynamics [N4].
• ResMed announced the sale of its MatrixCare business for $490 million to focus on core growth areas [S1].
• Market conditions showed stocks rallying on earnings and a favorable US payroll report, impacting healthcare stocks including ResMed [N3].
• Industry peers like Inogen cut 2026 revenue outlook due to channel pressures, indicating competitive and market challenges [N1].

ResMed benefits from increasing global awareness and diagnosis of sleep and respiratory disorders, which remain underpenetrated markets. Its expanding product portfolio, including new devices and digital health applications, supports improved patient outcomes and therapy adherence. The company's cloud-connected solutions enable efficient remote patient management, aligning with healthcare trends toward home-based care and cost reduction. Growth in both Sleep and Breathing Health and Residential Care Software segments, supported by acquisitions and geographic expansion, provides multiple avenues for revenue diversification. Strong liquidity and ongoing R&D investment position ResMed to capitalize on emerging clinical and technological opportunities.

ResMed faces risks from supply chain disruptions, including reliance on single-source suppliers and global trade uncertainties, which could impact product availability and costs. Regulatory and reimbursement changes in key markets may affect product adoption and pricing. Competition from other medical device manufacturers and software providers could pressure market share and margins. Patient compliance challenges and evolving treatment alternatives, including pharmaceutical therapies, may reduce demand for traditional devices. Additionally, divestiture of non-core businesses may impact revenue diversification. Macroeconomic factors and geopolitical risks could also affect global operations and financial performance.

ResMed's moat is built on its leadership in digital health and cloud-connected medical devices for sleep and breathing disorders, supported by a broad product portfolio including CPAP devices, ventilators, masks, and diagnostic tools. Its integrated cloud-based software applications enhance patient adherence and provider efficiency, creating a connected care ecosystem that is difficult to replicate. The company's global distribution network, established relationships with healthcare providers and HME suppliers, and ongoing investment in R&D and clinical studies further strengthen its competitive position. Additionally, regulatory certifications and quality management systems provide barriers to entry. The combination of innovative technology, comprehensive solutions, and global reach contributes to ResMed's defensibility in its markets.

• Supply Chain Disruptions: ResMed relies on multiple suppliers, including some single-source providers, for components and materials. Disruptions or constraints, such as semiconductor shortages or transport delays, could limit manufacturing capacity and product availability.
• Regulatory and Reimbursement Changes: Changes in healthcare regulations, reimbursement policies, or tariffs in various countries could impact product pricing, market access, and profitability.
• Competitive Pressure: The medical device and healthcare software markets are competitive, with risks from new entrants, alternative therapies, and evolving technologies that could erode market share.
• Patient Compliance and Treatment Alternatives: Effectiveness of CPAP and related therapies depends on patient adherence. Emerging pharmaceutical treatments and alternative devices may reduce demand for ResMed's products.
• Portfolio Optimization Risks: Divestiture of the MatrixCare business may reduce revenue diversification and expose the company to concentration risks in core segments.

• ResMed Inc is a global leader in digital health and cloud-connected medical devices focused on sleep and breathing health and residential care software solutions [S1].
• The company operates two main segments: Sleep and Breathing Health, and Residential Care Software [S1].
• Sleep and Breathing Health products include CPAP devices, bilevel devices, ventilators, masks, headgear, accessories, and diagnostic products for conditions such as obstructive sleep apnea (OSA), chronic obstructive pulmonary disease (COPD), and neuromuscular diseases [S1].
• ResMed's products are designed to improve patient outcomes, reduce chronic disease impact, and lower healthcare costs by enabling home-based care and connected health management [S1].
• The company has expanded through acquisitions, including Noctrix Health in 2026 (restless legs syndrome device) and VirtuOx in 2025 (independent diagnostic testing facility) [S1].
• ResMed sells products in over 140 countries through subsidiaries and independent distributors, with direct sales in some countries and partnerships with home medical equipment (HME) providers [S1].
• The Residential Care Software segment provides management software to healthcare providers in residential care settings, including Brightree in the U.S. and MEDIFOX DAN in Germany [S1].
• In June 2026, ResMed agreed to sell its MatrixCare business for $490 million to focus on core growth areas [S1].
• The company invests significantly in research and development, spending $94.3 million in Q3 2026 (6.6% of net revenues) on new product development and enhancements [S5].
• Recent product innovations include the AirSense 11 device with touch screen, new algorithms, digital enhancements, and over-the-air updates, plus the myAir app for patient coaching and compliance [S5].
• ResMed's manufacturing is globally distributed with quality certifications including ISO 13485 and FDA QMSR, but supply chain risks exist due to reliance on some single-source suppliers and global trade uncertainties [S3].
• The company reported net income of $1.523 billion and basic EPS of $10.47 for fiscal year ended June 30, 2026, with a current ratio of 3.1 and cash ratio of 1.05, indicating strong liquidity [S1, sec_financial_snapshot].
• Net revenue for the three months ended March 31, 2026 was $1.431 billion, an 11% increase year-over-year, driven by growth in devices and masks across all regions [S5].
• Sleep and Breathing Health segment revenue increased 11% for the nine months ended March 31, 2026 to $3.686 billion, with device sales up 9% and masks and other sales up 14% [S6].
• Residential Care Software revenue grew 6% for the nine months ended March 31, 2026 to $503.9 million, with growth in MEDIFOX DAN and HME verticals partially offset by weaker senior living performance [S6].
• The company had cash and cash equivalents of approximately $1.47 billion as of June 30, 2026, with available liquidity including revolving credit facilities totaling over $3 billion [S13, S17].
• ResMed repurchased shares under an ongoing program, with $325 million spent in the six months ended December 31, 2025, and pays regular dividends [S22].
• Recent news highlights include Q4 earnings call and results showing revenue growth and earnings increases, with stock price declines despite positive financial results [N2, N4, N5].
• The company faces risks including supply chain disruptions, regulatory changes, reimbursement pressures, and competition in the medical device and software markets [S1, S2].